share_log

JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $22

Benzinga ·  Nov 30, 2023 14:31

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and lowers the price target from $25 to $22.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment